Update on glucocorticoid-induced osteoporosis.
Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and fractures are the most frequent adverse effects of this medication. Glucocorticoids have several direct and indirect adverse effects on bone, primarily through reduction in osteoblasts and osteocyte activity, and life span. Recent advances in the pathophysiology and prevention of this complication of therapy provide hope for its amelioration in patients being treated with glucocorticoids. Several effective pharmacologic agents are now available, and guidelines for the prevention and treatment of GIOP have been published. Despite these advances, many patients still do not receive proper prevention or therapy.
Department of Medicine, University of Arizona School of Medicine, 1501 North Campbell, Tucson, AZ 85724, USA. mikemaricic@msn.com
Michael
M
Maricic
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000453:epidemiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy / Q000453:epidemiology; D012307:Risk Factors
D050071:Bone Density Conservation Agents; D005938:Glucocorticoids